Phase 1 Trial of Temozolomide (TMZ) plus Irinotecan (CPT-11) plus O(6)-Benzylguanine (O(6)-BG) in Adults with Recurrent Malignant Glioma

BACKGROUND: This is a phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG). The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Quinn, Jennifer A., Jiang, Sara Xiaoyin, Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Gururangan, Sridharan, Sampson, John H., McLendon, Roger E., Herndon, James E., Friedman, Henry S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2009
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748258/
https://ncbi.nlm.nih.gov/pubmed/19402172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24336
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia